Source: American Academy of Ophthalmology
Tuesday, November 13, 2007
Susan Desmond-Hellmann, MD, MPH, president of product development for Genentech, said she came to speak at today’s Retina Subspecialty Day program to assure physicians of two things: “One, Genentech will not interfere with your prescribing choice. Two, Genentech will do everything possible to ensure patients have access to Lucentis,” she said.
Full Story